Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer

Koji Ando, Eiji Oki, Hiroshi Saeki, Yuta Kasagi, Yasuo Tsuda, Yoko Zaitsu, Yuichiro Nakashima, Yu Imamura, Kippei Ohgaki, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background: Adjuvant chemotherapy (ACT) may prevent recurrence in patients with stage III colorectal cancer (CRC). However, only 10% of patients benefit from ACT and no effective indicators exist to predict which patients are likely to benefit. The present study validated metastatic lymph node (MLN) number as a new indicator for ACT. Patients and Methods: We retrospectively reviewed 173 patients with stage III CRC, who were classified by Union for International Cancer Control (UICC) stage or N category, and analyzed their overall survival (OS) and disease-free survival (DFS) according to stage, number of MLNs and ACT use. Results: Among 173 patients, we found 65 with only one MLN (N1a). For N1a patients treated with ACT, the 5-year OS rate was 100%; the 3-year DFS rate was 92.7% for those treated with oral ACT. Conclusion: The number of MLNs is a simple indicator for ACT in patients with stage III CRC. For patients with only one MLN, oral chemotherapy is a good option.

Original languageEnglish
Pages (from-to)6207-6211
Number of pages5
JournalAnticancer research
Volume35
Issue number11
Publication statusPublished - Nov 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Number of lymph node metastases may indicate the regimen for adjuvant chemotherapy in patients with stage III colorectal cancer'. Together they form a unique fingerprint.

Cite this